NGeneBio（A354200）株式概要体外診断用医薬品のコンパニオン診断薬やバイオインフォマティクスソフトウェアを開発。 詳細A354200 ファンダメンタル分析スノーフレーク・スコア評価2/6将来の成長0/6過去の実績0/6財務の健全性3/6配当金0/6報酬過去5年間の収益は年間7.5%増加しました。 リスク分析過去1年間で株主の希薄化は大幅に進んだ 意味のある時価総額がありません ( ₩20B )すべてのリスクチェックを見るA354200 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.Your Fair Value₩Current Price₩737.0067.9% 割安 内在価値ディスカウントGrowth estimate overAnnual revenue growth rate5 Yearstime period%/yrDecreaseIncreasePastFuture-13b31b2016201920222025202620282031Revenue ₩31.2bEarnings ₩5.8bAdvancedSet Fair ValueView all narrativesNGeneBio Co., Ltd. 競合他社MOA Life PlusSymbol: KOSDAQ:A142760Market cap: ₩23.6bPoongjeon PharmacyLTDSymbol: KOSDAQ:A298060Market cap: ₩21.8bEutilex.Co.LtdSymbol: KOSDAQ:A263050Market cap: ₩35.3bXcell TherapeuticsSymbol: KOSDAQ:A373110Market cap: ₩21.4b価格と性能株価の高値、安値、推移の概要NGeneBio過去の株価現在の株価₩737.0052週高値₩2,765.0052週安値₩736.00ベータ0.751ヶ月の変化-36.90%3ヶ月変化-60.59%1年変化-64.14%3年間の変化-89.08%5年間の変化-96.75%IPOからの変化-97.13%最新ニュースお知らせ • Apr 28NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,150,000 Price\Range: KRW 3135 Transaction Features: Rights OfferingNew Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩34b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩34b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.4b market cap, or US$28.8m).お知らせ • Mar 12NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South KoreaNew Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.2b market cap, or US$36.2m).New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩48.9b market cap, or US$33.1m).Reported Earnings • Nov 16Third quarter 2025 earnings released: ₩91.85 loss per share (vs ₩226 loss in 3Q 2024)Third quarter 2025 results: ₩91.85 loss per share (improved from ₩226 loss in 3Q 2024). Revenue: ₩5.43b (up 162% from 3Q 2024). Net loss: ₩1.85b (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.最新情報をもっと見るRecent updatesお知らせ • Apr 28NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,150,000 Price\Range: KRW 3135 Transaction Features: Rights OfferingNew Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩34b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩34b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.4b market cap, or US$28.8m).お知らせ • Mar 12NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South KoreaNew Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.2b market cap, or US$36.2m).New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩48.9b market cap, or US$33.1m).Reported Earnings • Nov 16Third quarter 2025 earnings released: ₩91.85 loss per share (vs ₩226 loss in 3Q 2024)Third quarter 2025 results: ₩91.85 loss per share (improved from ₩226 loss in 3Q 2024). Revenue: ₩5.43b (up 162% from 3Q 2024). Net loss: ₩1.85b (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.お知らせ • Oct 24NGeneBio Co., Ltd. announced that it has received KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On October 23, 2025, NGeneBio Co., Ltd. closed the transaction,お知らせ • Oct 17NGeneBio Co., Ltd. announced that it expects to receive KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.NGeneBio Co., Ltd. announced a private placement to issue series 6 unregistered interest unsecured private convertible bonds for gross proceeds of KRW 25,000,000,000 on October 15, 2025. The transaction includes participation from new investors, Baro Savings Bank for KRW 11,000,000,000, Sangsangin Savings Bank for KRW 11,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 3,000,000,000. The bonds have coupon rate of 2% and yield to maturity of 6%. The bonds will mature on October 23, 2028. The bonds will be 100% converted into 14,671,361 common shares at a fixed conversion price of KRW 1,704 per share. The conversion period is from October 23, 2026 to September 23, 2028. The payment date of the transaction is October 23, 2025. The transaction has been approved by the board of directors of the company. The transaction is subject to prohibition of conversion and recommended split for one year from the date of issuance of debentures.お知らせ • Jun 13NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million.NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 533,616 Price\Range: KRW 1874 Transaction Features: Subsequent Direct Listingお知らせ • Jun 07NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 533,616 Price\Range: KRW 1874 Transaction Features: Subsequent Direct Listingお知らせ • Jun 06NGeneBio Co., Ltd. announced that it expects to receive KRW 999.996384 million in fundingNGeneBio Co., Ltd. announced a private placement to issue 533,616 common shares at an issue price of KRW 1.874 for gross proceeds of KRW 999,996,384 on June 5, 2025. The transaction will include participation from new investors Farmers Alibaba Co. , Ltd 213,447 shares, Lee Deok-yong 213,447 shares, Oh wajong 53,361 shares and Hwang Yunseong shares. The transaction has been approved shareholders, restricted to a hold period, expected to close on June 13, 2025.お知らせ • Jun 04SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200).SH Healthcare Investment No. 1 Fund and others entered into an agreement to acquire 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) for KPW 2.2 billion on May 16, 2025. A cash consideration valued at KPW 1596.2 per share will be paid by SH Healthcare Investment No. 1 Fund. As part of consideration, an undisclosed value is paid towards common equity of NGeneBio Co., Ltd. After the transaction KT Corporation will completely exit from target and SH Healthcare Investment No. 1 Fund will hold 6.1% in target. The expected completion of the transaction is June 2, 2025. SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) on June 2, 2025.New Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩6.9b revenue, or US$5.0m). Market cap is less than US$100m (₩39.9b market cap, or US$29.0m).分析記事 • Apr 17Is NGeneBio (KOSDAQ:354200) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...New Risk • Apr 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩5.7b revenue, or US$3.9m). Market cap is less than US$100m (₩30.7b market cap, or US$20.9m).お知らせ • Mar 07NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South KoreaNew Risk • Jan 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩34.5b market cap, or US$23.4m).New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$21.7m).分析記事 • Dec 05Is NGeneBio (KOSDAQ:354200) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Dec 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Revenue is less than US$5m (₩6.2b revenue, or US$4.4m). Market cap is less than US$100m (₩35.4b market cap, or US$25.2m).お知らせ • Apr 17J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion.J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3.2 billion on April 3, 2024. The deal is expected to be completed on April 15, 2024.J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion on April 15, 2024. J&L Agent paid KRW 2.96 billion for acquisition of NGeneBio.New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 61% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.2m). Market cap is less than US$100m (₩79.9b market cap, or US$59.2m).分析記事 • Mar 14Is NGeneBio (KOSDAQ:354200) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...New Risk • Sep 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 49% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Revenue is less than US$5m (₩5.9b revenue, or US$4.4m). Market cap is less than US$100m (₩75.2b market cap, or US$55.5m).お知らせ • Sep 02NGeneBio Co., Ltd. announced that it has received KRW 20 billion in fundingOn September 1, 2022, NGeneBio Co., Ltd. closed the transaction.株主還元A354200KR BiotechsKR 市場7D-15.8%-9.0%-6.6%1Y-64.1%2.9%147.7%株主還元を見る業界別リターン: A354200過去 1 年間で2.9 % の収益を上げたKR Biotechs業界を下回りました。リターン対市場: A354200は、過去 1 年間で147.7 % のリターンを上げたKR市場を下回りました。価格変動Is A354200's price volatile compared to industry and market?A354200 volatilityA354200 Average Weekly Movement11.6%Biotechs Industry Average Movement10.6%Market Average Movement8.9%10% most volatile stocks in KR Market16.2%10% least volatile stocks in KR Market4.6%安定した株価: A354200 、 KR市場と比較して、過去 3 か月間で大きな価格変動はありませんでした。時間の経過による変動: A354200の 週次ボラティリティ ( 12% ) は過去 1 年間安定しています。会社概要設立従業員CEO（最高経営責任者ウェブサイト201556Min-sik Kimngenebio.com/kr/体外診断用医薬品のコンパニオン診断薬やバイオインフォマティクスソフトウェアを開発。BRCAaccuTestおよびBRCAaccuTest PLUSは乳がんおよび卵巣がん、遺伝性乳がんおよび卵巣がん症候群の試薬キット、HEMEaccuTestは急性骨髄性白血病、急性リンパ性白血病、骨髄異形成性/骨髄増殖性新生物、多発性骨髄腫、リンパ腫などの血液悪性腫瘍の臨床NGSキット；SOLIDaccuTest：固形がんの遺伝子変異スクリーニング、HLAaccuTest：ヒト白血球抗原タイピングのための体外診断用医療機器、OncoaccuPanel：固形がんの次世代シーケンシング検査。また、遺伝子検査データの解析用ソフトウェアNGeneAnalySys、NGSのデータを用いて組織適合抗原のヒト白血球抗原を同定するHLAタイピングを提供するEasyHLAanalyzerも提供している。さらに、家族関係検査、同一性検査、法医学、キメリズム解析のためのショートタンデムリピート検査であるIDaccuTest、COVID-19に感染している、またはその疑いのある患者からSARS-CoV-2の核酸を定性的に検出することを目的としたリアルタイム逆転写ポリメラーゼ連鎖反応アッセイの試薬であるNGenePlex nCoV qRT-PCR Kitを提供している。同社は2015年に設立され、韓国のソウルに本社を置いている。もっと見るNGeneBio Co., Ltd. 基礎のまとめNGeneBio の収益と売上を時価総額と比較するとどうか。A354200 基礎統計学時価総額₩19.76b収益（TTM）-₩4.41b売上高(TTM)₩31.20b0.6xP/Sレシオ-4.5xPER（株価収益率A354200 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計A354200 損益計算書（TTM）収益₩31.20b売上原価₩26.96b売上総利益₩4.24bその他の費用₩8.66b収益-₩4.41b直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）-164.65グロス・マージン13.60%純利益率-14.15%有利子負債／自己資本比率145.8%A354200 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/23 22:41終値2026/06/22 00:00収益2026/03/31年間収益2025/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社の Github ページ でご覧いただけます。また、レポートの使い方に関する ガイド や YouTube の チュートリアル もご用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋NGeneBio Co., Ltd. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Apr 28NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,150,000 Price\Range: KRW 3135 Transaction Features: Rights Offering
New Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩34b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩34b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.4b market cap, or US$28.8m).
お知らせ • Mar 12NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea
New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.2b market cap, or US$36.2m).
New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩48.9b market cap, or US$33.1m).
Reported Earnings • Nov 16Third quarter 2025 earnings released: ₩91.85 loss per share (vs ₩226 loss in 3Q 2024)Third quarter 2025 results: ₩91.85 loss per share (improved from ₩226 loss in 3Q 2024). Revenue: ₩5.43b (up 162% from 3Q 2024). Net loss: ₩1.85b (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Apr 28NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 22.41525 billion. Security Name: Common Stock Security Type: Common Stock Securities Offered: 7,150,000 Price\Range: KRW 3135 Transaction Features: Rights Offering
New Risk • Apr 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩34b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩34b free cash flow). Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 1.3% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩43.4b market cap, or US$28.8m).
お知らせ • Mar 12NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2026, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea
New Risk • Mar 01New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 32% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 10% per year over the past 5 years. Shareholders have been substantially diluted in the past year (32% increase in shares outstanding). Minor Risk Market cap is less than US$100m (₩52.2b market cap, or US$36.2m).
New Risk • Jan 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Earnings have declined by 10% per year over the past 5 years. Minor Risks Share price has been volatile over the past 3 months (10% average weekly change). Shareholders have been diluted in the past year (26% increase in shares outstanding). Market cap is less than US$100m (₩48.9b market cap, or US$33.1m).
Reported Earnings • Nov 16Third quarter 2025 earnings released: ₩91.85 loss per share (vs ₩226 loss in 3Q 2024)Third quarter 2025 results: ₩91.85 loss per share (improved from ₩226 loss in 3Q 2024). Revenue: ₩5.43b (up 162% from 3Q 2024). Net loss: ₩1.85b (loss narrowed 36% from 3Q 2024). Over the last 3 years on average, earnings per share has increased by 8% per year but the company’s share price has fallen by 41% per year, which means it is significantly lagging earnings.
お知らせ • Oct 24NGeneBio Co., Ltd. announced that it has received KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.On October 23, 2025, NGeneBio Co., Ltd. closed the transaction,
お知らせ • Oct 17NGeneBio Co., Ltd. announced that it expects to receive KRW 25 billion in funding from Baro Savings Bank, Sangsangin Savings Bank, Sangsangin Plus Savings Bank Co.,Ltd.NGeneBio Co., Ltd. announced a private placement to issue series 6 unregistered interest unsecured private convertible bonds for gross proceeds of KRW 25,000,000,000 on October 15, 2025. The transaction includes participation from new investors, Baro Savings Bank for KRW 11,000,000,000, Sangsangin Savings Bank for KRW 11,000,000,000 and Sangsangin Plus Savings Bank Co.,Ltd. for KRW 3,000,000,000. The bonds have coupon rate of 2% and yield to maturity of 6%. The bonds will mature on October 23, 2028. The bonds will be 100% converted into 14,671,361 common shares at a fixed conversion price of KRW 1,704 per share. The conversion period is from October 23, 2026 to September 23, 2028. The payment date of the transaction is October 23, 2025. The transaction has been approved by the board of directors of the company. The transaction is subject to prohibition of conversion and recommended split for one year from the date of issuance of debentures.
お知らせ • Jun 13NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million.NGeneBio Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.996384 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 533,616 Price\Range: KRW 1874 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 07NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million.NGeneBio Co., Ltd. has filed a Follow-on Equity Offering in the amount of KRW 999.996384 million. Security Name: Common Stock Security Type: Common Stock Securities Offered: 533,616 Price\Range: KRW 1874 Transaction Features: Subsequent Direct Listing
お知らせ • Jun 06NGeneBio Co., Ltd. announced that it expects to receive KRW 999.996384 million in fundingNGeneBio Co., Ltd. announced a private placement to issue 533,616 common shares at an issue price of KRW 1.874 for gross proceeds of KRW 999,996,384 on June 5, 2025. The transaction will include participation from new investors Farmers Alibaba Co. , Ltd 213,447 shares, Lee Deok-yong 213,447 shares, Oh wajong 53,361 shares and Hwang Yunseong shares. The transaction has been approved shareholders, restricted to a hold period, expected to close on June 13, 2025.
お知らせ • Jun 04SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200).SH Healthcare Investment No. 1 Fund and others entered into an agreement to acquire 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) for KPW 2.2 billion on May 16, 2025. A cash consideration valued at KPW 1596.2 per share will be paid by SH Healthcare Investment No. 1 Fund. As part of consideration, an undisclosed value is paid towards common equity of NGeneBio Co., Ltd. After the transaction KT Corporation will completely exit from target and SH Healthcare Investment No. 1 Fund will hold 6.1% in target. The expected completion of the transaction is June 2, 2025. SH Healthcare Investment No. 1 Fund and others completed the acquisition of 6.80% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from KT Corporation (KOSE:A030200) on June 2, 2025.
New Risk • Jun 02New major risk - Revenue and earnings growthEarnings have declined by 19% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 19% per year over the past 5 years. Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩6.9b revenue, or US$5.0m). Market cap is less than US$100m (₩39.9b market cap, or US$29.0m).
分析記事 • Apr 17Is NGeneBio (KOSDAQ:354200) Using Debt Sensibly?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
New Risk • Apr 01New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩13b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩13b free cash flow). Shareholders have been substantially diluted in the past year (54% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩5.7b revenue, or US$3.9m). Market cap is less than US$100m (₩30.7b market cap, or US$20.9m).
お知らせ • Mar 07NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025NGeneBio Co., Ltd., Annual General Meeting, Mar 31, 2025, at 09:01 Tokyo Standard Time. Location: conference room, guro-gu, seoul South Korea
New Risk • Jan 11New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 53% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Shareholders have been substantially diluted in the past year (53% increase in shares outstanding). Minor Risks Share price has been volatile over the past 3 months (12% average weekly change). Revenue is less than US$5m (₩6.2b revenue, or US$4.2m). Market cap is less than US$100m (₩34.5b market cap, or US$23.4m).
New Risk • Dec 16New major risk - Financial data availabilityThe company has not reported any financial data. This is considered a major risk. With no or incomplete audited reported financial data, it is virtually impossible to assess the company's investment potential. Currently, the following risks have been identified for the company: Major Risks No financial data reported. Share price has been highly volatile over the past 3 months (16% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Market cap is less than US$100m (₩31.1b market cap, or US$21.7m).
分析記事 • Dec 05Is NGeneBio (KOSDAQ:354200) Using Too Much Debt?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Dec 03New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -₩15b This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-₩15b free cash flow). Share price has been highly volatile over the past 3 months (17% average weekly change). Minor Risks Shareholders have been diluted in the past year (6.6% increase in shares outstanding). Revenue is less than US$5m (₩6.2b revenue, or US$4.4m). Market cap is less than US$100m (₩35.4b market cap, or US$25.2m).
お知らせ • Apr 17J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion.J&L Agent Co., Ltd. and other buyer agreed to acquire 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3.2 billion on April 3, 2024. The deal is expected to be completed on April 15, 2024.J&L Agent Co., Ltd. and other buyer completed the acquisition of 4.97% stake in NGeneBio Co., Ltd. (KOSDAQ:A354200) from Gencurix Inc. (KOSDAQ:A229000) for KRW 3 billion on April 15, 2024. J&L Agent paid KRW 2.96 billion for acquisition of NGeneBio.
New Risk • Apr 03New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 8.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 61% over the past year. Minor Risks Share price has been volatile over the past 3 months (8.3% average weekly change). Shareholders have been diluted in the past year (2.2% increase in shares outstanding). Revenue is less than US$5m (₩4.4b revenue, or US$3.2m). Market cap is less than US$100m (₩79.9b market cap, or US$59.2m).
分析記事 • Mar 14Is NGeneBio (KOSDAQ:354200) Weighed On By Its Debt Load?Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Risk • Sep 27New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 2.4% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risk Revenue has declined by 49% over the past year. Minor Risks Less than 3 years of financial data is available. Share price has been volatile over the past 3 months (12% average weekly change). Shareholders have been diluted in the past year (2.4% increase in shares outstanding). Revenue is less than US$5m (₩5.9b revenue, or US$4.4m). Market cap is less than US$100m (₩75.2b market cap, or US$55.5m).
お知らせ • Sep 02NGeneBio Co., Ltd. announced that it has received KRW 20 billion in fundingOn September 1, 2022, NGeneBio Co., Ltd. closed the transaction.
